Commercialisation is underway
Outlook | 2 May 2017
Commercialisation is underway
Outlook | 2 May 2017
Share this note
The challenge for Sphere Medical over the next 12 months is to transition a promising technology platform into a viable commercial operation. The receipt of the CE Mark in late-16 led to Proxima 4 being launched across several major European markets. An increasing number of hospitals have begun clinical evaluations, and the focus over the coming year is translating these expressions of interest into meaningful sales. We remind that we estimate that Sphere Medical will likely have a funding requirement of £7-8m (excluding the Silicon Valley Bank loan facility) in 2017. Our valuation, based on a three-phase DCF-based model, remains unchanged at £30.2m, equivalent to 21.3p per share.
|Adj. PBT (£m)||(6.0)||(5.1)||(6.2)||(5.7)|
|Net Income (£m)||(5.5)||(4.5)||(5.7)||(5.3)|
|Adj. EPS (p)||(5.3)||(3.2)||(3.9)||(3.6)|
2 May 2017
|Shares in issue||141.8m|
|12 month range||5.0-14.5p|
|Primary exchange||AIM London|
Sphere Medical develops and commercialises medical monitoring and diagnostic equipment. Its lead product, Proxima, provides near real-time analysis of blood gases, electrolytes, and metabolites at the patient’s bedside within critical care.
+44 20 3637 5041
Mick Cooper PhD
+44 (0) 20 3637 5042
Having launched the Proxima 4 device across several major European markets, the focus for the next 12 months is gaining meaningful sales traction. Whilst the rising number of clinical evaluations suggest this is progressing well, the lengthy sales cycle, coupled with further spend on product development, means cash out-flows are expected over the near term. Our forecasts show an overall funding requirement over the coming year of £7-8m. Our valuation, based on a three-phase DCF model, is unchanged at £30.2m (21.3p a share).
Sphere Medical has achieved a number of important milestones in the past 12 months. These include the receipt of the CE Mark for the Proxima 4 system in September 2016; the first sales in direct markets in Europe; the appointment of distributors in Italy, Spain, and now Austria; improving the connectivity with leading patient data systems; demonstrating the workflow benefits of using Proxima on critically ill, unstable patients; and completing the production facility in St Asaph, North Wales. Over the coming 12 months the emphasis is firmly on establishing a solid commercial platform and translating the healthy pipeline of clinical interest into meaningful sales traction.
Changing established clinical practise can be a major challenge, with numerous well-documented cases of products and technologies with proven clinical and economic benefits taking time to establish themselves. In part this reflects the complexity of purchase decisions within individual hospitals, with clinical evaluations being required to demonstrate the procedure’s merits and to understand how its use will impact existing clinical practises. The experience with previous generations of Proxima suggests the lead time from first meaningful contact to an order being placed lies between 9 and 12 months.
Following its launch in December 2016 over 40 hospitals have initiated the assessment process, with 30 having had the product demonstrated in their clinical setting. Of these 14 have conducted evaluations, with Proxima 4 being connected to real patients in a real setting, and six (across three countries) have progressed to placing their first orders. These figures compare to the 20 hospitals expressing an interest and 4 performing a clinical evaluation disclosed with the 2016 trading update in February 2017.
Proxima 4 is the latest generation of the Proxima micro-analyser platform and represents a major upgrade to the previous generations. As well as additional functionality (notably glucose analysis), direct connectivity with hospital information systems (including Conworx and Clinisys), and simpler and quicker set-up, a major advance with Proxima 4 has been its indicated use being broadened to adult patients undergoing major procedures (such as neuro and cardiac surgery) and in children heavier than 15Kg. Interestingly, the Royal Manchester Children’s Hospital has become the first to place an order for paediatric use. This underscores a key feature with Proxima in that it is an in-line “closed system“, with all patient blood being returned, and such blood conservation is even more critical in paediatric applications.
Sphere Medical has appointed Eumedics Medizintechnik GmbH as its distributor in Austria. This adds to Burke & Burke, who were appointed distributors for Italy in July 2016, and Proyectos Hospitalarios Internacional (Prhoinsa), who were appointed distributors for Spain in December 2016. Burke & Burke have completed training and have started their marketing campaign, with Prhoinsa due to start theirs imminently. Additional regional partners are expected to be confirmed during the year, with a target of having a sales presence that addresses 60% of the European Union by the end of 2017. The key priority is the securing of a network of local partners that are committed and capable of maximising the commercial potential of Proxima 4.
We last updated our model when the CE Mark effectively removed regulatory risk from our investment case. Our valuation remains unchanged at £30.2m (equivalent to 21.3p a share). We value Sphere Medical using a three-phase DCF model, assuming a discount rate of 10%, terminal growth of 2% and a long-term tax rate of 20% (not reflecting the potential benefits of the Patent Box incentives). We also ascribe an 80% probability of success to the Proxima cash flows (previously 60%, which included regulatory risk) to take into account the commercialisation risk until additional distributors are appointed. The breakdown of our valuation is shown in Exhibit 1.
In modelling our sales adoption for Proxima 4 (and Proxima 4+ from 2018), we have taken note that the sales cycles for such products tends to be protracted, as equipment that can change clinical practice usually has longer assessment periods, which means meaningful revenue is not expected to flow through until 2018. We estimate the sensor, calibration solutions and flushes are priced at £200 and the monitor and stand are effectively leased out for a nominal sum. Such pricing suggests that if a patient is expected to need around 8-10 blood gas measurements per day then the Proxima systems should become cost-effective and effectively defines the target population.
We have adopted conservative assumptions throughout in our modelling; for instance, the valuation includes only the sales for use in the critical care settings, with no value assigned to its possible use in other settings, neither does it consider the inherent value of the technology platform. We feel this is currently appropriate as Sphere Medical has yet to demonstrate successful execution of its commercialisation strategy; however, as visibility improves we envisage employing less cautious assumptions.
Notably, we also ascribe no value to potential cash flows from other markets such as the US and Japan (or even RoW markets that recognise CE Marking) at present until such times as the company confirms its strategy for these key regions. Clearly as progress is achieved, we would expect to revisit the model and anticipate the valuation would reflect this.
Our forecast suggest the lengthy sales cycles, coupled with continuing development expenditure, results in cash out-flows for the coming years. At FY16 the cash out-flow from operating activities was £4.5m (from £5.1m in FY15), with cash and cash equivalents of £3.2m at December 2016, down from £10.0m the previous year-end. In January 2017 a £3.0m loan facility from Silicon Valley Bank was established, being repayable by 2020. An initial £1.5m was drawn down at the time, with a further £1.5m conditionally available until March 2018. We remind that we estimate that Sphere Medical will likely have a funding requirement of £7-8m during 2017, which is shown as short term debt for the purposes of our forecasts.
We have taken the opportunity to fine-tune our expectations for the near-term, notably on the revenue line. This reflects mainly the phasing of sales to distributors, including those expected to be appointed. The change is minor, with the FY17 revenue line dropping from £690,000 to £378,000 (see Exhibit 2).
 In a closed system all the blood samples are conserved and re-infused into the patient. In open systems these would be directed to waste, with the attendant issues of blood loss and contamination.
Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.
ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.
In the preparation of this report TDRL has used publically available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.
Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.
This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.
Copyright 2017 Trinity Delta Research Limited. All rights reserved.